Cardium Reports on First Quarter 2008 Highlights and Financi... (pdf . Cardium's InnerCool Therapies s...)

Cardium Reports on First Quarter 2008 Highlights and Financial Results

Date:5/9/2008

pdf.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and therapeutic hypothermia, including InnerCool's Celsius Control System(TM), which has received regulatory clearance in the U.S., Europe and Australia, and its CoolBlue(TM) surface-based system, which is currently being marketed in the U.S., please visit http://www.innercool.com.

Cardium's Tissue Repair Company subsidiary (TRC) is a San Diego-based biopharmaceutical company focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate(TM), is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate(TM) is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot ulcers. Other potential applications for TRC's Gene Activated Matrix(TM) (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit http://www.t-r-co.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variet
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
2. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
3. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
4. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
5. Cardium Completes $5.3 Million Registered Direct Offering
6. Cardium Announces $5.3 Million Registered Direct Offering
7. Novavax Reports First Quarter 2008 Financial Results
8. Warner Chilcott Reports Operating Results for the Quarter ended March 31, 2008 and Updates 2008 Full Year Guidance
9. Biodel Inc. Reports Second Quarter Fiscal Year 2008 Financial Results
10. Pharmos Corporation Reports 2008 First Quarter Results
11. Halozyme Therapeutics Reports 2008 First Quarter Financial Results

Post Your Comments:

Cardium Reports on First Quarter 2008 Highlights and Financi...(pdf . Cardium's InnerCool Therapies s...)